Novel hemostatic biomolecules based on elastin-like polypeptides and the self-assembling peptide RADA-16

Area of Science:

• Biomaterials Science
• Molecular Biology
• Biotechnology

Background:

• Developing safe and effective hemostatic materials is crucial for reducing mortality from excessive hemorrhage.
• Gene recombination technology was employed to create novel biomaterials with hemostatic properties.

Purpose of the Study:

• To create and characterize fusion proteins by combining RADA-16 (a self-assembling peptide) with elastin-like polypeptides (ELPs).
• To evaluate the hemostatic efficacy and safety of these novel fusion proteins.

Main Methods:

• Fusion proteins (36R, 60R, 96R) were engineered by fusing RADA-16 to ELPs via gene recombination.
• Proteins were over-expressed in E. coli, purified using inverse phase transition and His-tag affinity chromatography.
• Hemostatic efficacy was assessed on mouse liver bleeding models, with comparisons to rat-tail collagen and RADA-16 on gauze.

Main Results:

• High purity (94-97%) fusion proteins were successfully prepared.
• The fusion proteins exhibited no significant cytotoxicity to L929 and HT22 cell lines.
• The 96R fusion protein demonstrated a potent hemostatic effect, with a clotting time of 15.85 ± 1.21 seconds, superior to rat-tail collagen and comparable to RADA-16 on gauze.

Conclusions:

• Gene recombination technology can yield effective fusion proteins for hemostatic applications.
• The developed fusion proteins represent a promising class of biomaterials for controlling hemorrhage.